+ Watch ALXN
on My Watchlist
A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.
I believe that this company's new cancer drug will draw in many investors over the next few months and the drug itself, which is in FDA review, looks like a definite winner. I suspect this stock to hit $65 , maybe as high as $80 by Q4 07.
And what if this cancer drug is not successful. This co is projected to lose $3.96 a share this year.If they dont start making money they will need to float more shares.$80 yeah sure. Take a few of these hyped up biotechs losing big money and practically no book value you will find it easy to beat the s&p. Its a crapshoot as to winning with this stock.
Drug was approved in March in the US and in June for Europe. First quarter of sales was expected to be $3mm and it turn out to be $9.8mm. This quarter sales are expected to be $15mm and we will learn in the end of October if they beat again. Right now with the stock at $69/sh it looks like the call of $80/sh by the 4Q07 looks like the right one...
You nailed this one. Kudos. I'm still amazed the street keeps propping this up. I wish I could put my red thumb on now instead of last year.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions